Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

Kuehne, Felicitas C; Bethe, Ullrich; Freedberg, Kenneth; Goldie, Sue J

Kuehne, Felicitas C; Bethe, Ullrich; Freedberg, Kenneth; Goldie, Sue J.

Affiliation

Kuehne FC; Harvard Program on the Economic Evaluation of Medical Technology, 718 Huntington Ave, Second Floor, Boston, MA 02115-5924, USA.

Arch Intern Med ; 162(22): 2545-56, 2002.

Article in En | MEDLINE | ID: mdl-12456226

Subject(s)

AIDS-Related Opportunistic Infections/drug therapy; AIDS-Related Opportunistic Infections/economics; Health Care Costs; Hepatitis C, Chronic/drug therapy; Hepatitis C, Chronic/economics; Quality of Life; AIDS-Related Opportunistic Infections/mortality; Adult; Antiviral Agents/administration & dosage; Antiviral Agents/economics; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic/mortality; Humans; Interferon alpha-2; Interferon-alpha/administration & dosage; Interferon-alpha/economics; Male; Markov Chains; Middle Aged; Models, Statistical; Recombinant Proteins; Survival Rate; Treatment Outcome; United States

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Health Care Costs / AIDS-Related Opportunistic Infections / Hepatitis C, Chronic Type of study: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Arch Intern Med Year: 2002 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links